Retatrutide Phase 3 Results: What People With Type 2 Diabetes Should Know 10th June 2026 by Living Diabetes Editorial Phase 3 retatrutide data in recent-onset type 2 diabetes showed A1C lowering and weight loss. The drug remains investigational and is not FDA-approved.
Tirzepatide Maintenance Study: What SURMOUNT-MAINTAIN Means 6th June 202622nd May 2026 by Living Diabetes Editorial Plain-language SURMOUNT-MAINTAIN summary covering continued tirzepatide, dose reduction, weight regain, study limits, and patient questions.
Obesity in Young Adults: What 2050 Projections Mean for Diabetes Prevention 6th June 202612th April 2025 by Living Diabetes Editorial Recent projections warn that obesity could become more common in young adults by 2050, raising concern for future diabetes and heart health.
